SEC Form 4 · accession 0001209191-19-003164
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
G Bradley Cole
Officer — CFO
Period of report
Jan 8, 2019
Accepted (ET)
Jan 9, 2019 · 7:43 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 8, 2019 | M | 5,000 | $17.18 | A | 49,047 | I | Held by the Cole Family Trust |
| Common StockF2,F3,F4,F1 | Jan 8, 2019 | S | 1,100 | $65.8955 | D | 47,947 | I | Held by the Cole Family Trust |
| Common StockF2,F3,F5,F1 | Jan 8, 2019 | S | 1,700 | $66.6796 | D | 46,247 | I | Held by the Cole Family Trust |
| Common StockF2,F3,F6,F1 | Jan 8, 2019 | S | 2,200 | $67.8592 | D | 44,047 | I | Held by the Cole Family Trust |
| Common StockF1 | Jan 8, 2019 | M | 10,000 | $22.98 | A | 54,047 | I | Held by the Cole Family Trust |
| Common StockF7,F3,F8,F1 | Jan 8, 2019 | S | 2,100 | $65.8712 | D | 51,947 | I | Held by the Cole Family Trust |
| Common StockF7,F3,F9,F1 | Jan 8, 2019 | S | 3,428 | $66.665 | D | 48,519 | I | Held by the Cole Family Trust |
| Common StockF7,F3,F10,F1 | Jan 8, 2019 | S | 4,472 | $67.8473 | D | 44,047 | I | Held by the Cole Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F11 | $17.18 | Jan 8, 2019 | M | 5,000 | D | — | Feb 18, 2020 | Common Stock | 5,000 | 31,471 | D |
| Employee Stock Option (right to buy)F12 | $22.98 | Jan 8, 2019 | M | 10,000 | D | — | Jan 27, 2021 | Common Stock | 10,000 | 36,424 | D |
Explanation of responses
- F1Includes an aggregate of 16,534 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F10Represents weighted average sale price. Actual sale prices ranged from $67.33 to $68.32.
- F11The option became exercisable as to 25% of the shares on February 18, 2011, and became exercisable as to 1/48th of the shares each full month thereafter.
- F12The option became exercisable as to 25% of the shares on January 27, 2012, and became exercisable as to 1/48th of the shares each full month thereafter.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 4, 2018.
- F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F4Represents weighted average sale price. Actual sale prices ranged from $65.32 to $66.26.
- F5Represents weighted average sale price. Actual sale prices ranged from $66.36 to $67.13.
- F6Represents weighted average sale price. Actual sale prices ranged from $67.42 to $68.32.
- F7These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 23, 2018.
- F8Represents weighted average sale price. Actual sale prices ranged from $65.28 to $66.25.
- F9Represents weighted average sale price. Actual sale prices ranged from $66.29 to $67.13.